Atlas Protocol · Clinical Prevention

Atlas ACMG Core

81-gene ACMG SF v3.2 secondary-findings panel — every actionable medically-actionable gene.

An 81-gene panel implementing the ACMG SF v3.2 list of medically actionable secondary findings — every gene where a positive finding leads to evidence-based clinical action.

GenDG §10

Bookable, after medical review.

Before the analysis, a specialist in human genetics reviews your preparation questionnaire and informs you (GenDG). If the test is declined, Atlas refunds the full amount.

HOW IT WORKS

How it works.

  1. 01

    Pay

    You pay Atlas for Atlas Baseline and the analysis.

  2. 02

    Questionnaire and physician review

    You receive a questionnaire by email from the physician's practice, and a specialist in human genetics reviews it. If the test is declined, you get a full automatic refund.

  3. 03

    Counselling slot

    You choose a counselling slot or join the waitlist.

  4. 04

    Consent, kit and result

    After the counselling you give your consent, then we ship your collection kit. The physician discusses the result with you.

WHICH PART OF YOUR BODY

Which part of your body.

  • Heart
  • Breasts
  • Colon
  • Liver
  • Kidneys
  • Brain
  • Muscle
WHAT THIS PANEL ANSWERS

What this panel answers.

Across every gene where international medical consensus says a finding leads to documented medical action, do you carry anything actionable?

WHAT CHANGES IF A FINDING IS IDENTIFIED

What changes if something is found.

  1. If a finding is identified, follow-up is established medical practice -- this is the international guideline-grade baseline.
  2. Cancer findings (BRCA1/2, Lynch, TP53) route to oncology surveillance and may qualify for the GC-HBOC program where applicable.
  3. Cardiac findings (channelopathies, cardiomyopathies, aortopathies) route to cardiology surveillance and, when indicated, electrophysiology evaluation.
  4. Metabolic findings (Wilson, Pompe, Fabry, OTC, biotinidase) route to specialist-led therapy planning.
  5. Cascade testing of first-degree relatives is part of the ACMG framework when an actionable variant is identified.
Pathway references
  • ACMG SF v3.2
  • GC-HBOC
  • GenDG §7
  • GKV
GENES ANALYZED

What is analyzed.

Atlas ACMG Core implements the American College of Medical Genetics and Genomics Secondary Findings list -- version 3.2 -- in full. Every gene on the panel is curated by ACMG specifically as a setting where pre-symptomatic identification leads to a documented medical action.

ACMG Secondary Findings v3.2 (Actionable Core)

81 genes

The American College of Medical Genetics and Genomics (ACMG) curates a list of genes -- updated through version 3.2 -- where a pre-symptomatic finding provides clear, evidence-based medical action. This 81-gene panel implements that list in full.

Clinical areas covered
  • Hereditary cancer syndromes
  • Cardiac channelopathies and cardiomyopathies
  • Aortopathies and connective-tissue disorders
  • Malignant hyperthermia susceptibility
  • Familial hypercholesterolemia
  • Wilson disease, Pompe, Fabry, biotinidase, OTC deficiency
Analyzed genes -- 81 genes
  • ACTA2
  • ACTC1
  • ACVRL1
  • APC
  • APOB
  • ATP7B
  • BAG3
  • BMPR1A
  • BRCA1
  • BRCA2
  • BTD
  • CACNA1S
  • CALM1
  • CALM2
  • CALM3
  • CASQ2
  • COL3A1
  • DES
  • DSC2
  • DSG2
  • DSP
  • ENG
  • FBN1
  • FLNC
  • GAA
  • GLA
  • HFE
  • HNF1A
  • KCNH2
  • KCNQ1
  • LDLR
  • LMNA
  • MAX
  • MEN1
  • MLH1
  • MSH2
  • MSH6
  • MUTYH
  • MYBPC3
  • MYH11
  • MYH7
  • MYL2
  • MYL3
  • NF2
  • OTC
  • PALB2
  • PCSK9
  • PKP2
  • PMS2
  • PRKAG2
  • PTEN
  • RB1
  • RBM20
  • RET
  • RPE65
  • RYR1
  • RYR2
  • SCN5A
  • SDHAF2
  • SDHB
  • SDHC
  • SDHD
  • SMAD3
  • SMAD4
  • STK11
  • TGFBR1
  • TGFBR2
  • TMEM127
  • TMEM43
  • TNNC1
  • TNNI3
  • TNNT2
  • TP53
  • TPM1
  • TRDN
  • TSC1
  • TSC2
  • TTN
  • TTR
  • VHL
  • WT1

Gene list version 2026-05 (ACMG SF v3.2). The ACMG list is reviewed and updated by the College; Atlas tracks the current version.

WHY THIS MATTERS

Why early knowledge matters.

  • ACMG Secondary Findings v3.2 (Actionable Core)

    ACMG SF v3.2 is the international reference for "actionable" predictive genetic findings. Each gene on the list has a documented intervention -- screening, surveillance, medication, or surgery -- that meaningfully changes outcomes when the variant is identified before disease appears.

RESULT INTERPRETATION

How findings are reported.

Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.

  1. 01

    Pathogenic variant

    Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.

  2. 02

    Likely pathogenic variant

    Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.

  3. 03

    Variant of uncertain significance (VUS)

    Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.

  4. 04

    No relevant variant in this panel

    No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.

  5. 05

    Family implications

    When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.

Module-specific implications

  • ACMG Secondary Findings v3.2 (Actionable Core)

    • Findings span cancer, cardiac, metabolic, and connective-tissue domains -- the appropriate specialist follow-up depends on which gene.
    • Cascade testing of first-degree relatives is part of the standard ACMG framework.
Counseling and cascade testing

Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). This counseling, before and after the test, is given by a specialist in human genetics. When an actionable finding has implications for relatives, this physician discusses cascade testing with you, not Atlas alone.

CLINICAL LIMITATIONS

What this test does not do.

  • Not a diagnosis of active disease

    A variant indicates predisposition. It does not confirm a condition is currently present.

  • Does not replace screening or routine care

    Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.

  • Not all risk is genetic

    Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.

  • A negative result does not eliminate risk

    Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.

  • Clinical decisions remain with your physician

    Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.

GenDG §7

Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. This counseling is given by a specialist in human genetics.

Ready to start?

Book →

Not sure if this is the right protocol? Let Atlas walk you through a few questions. Start Triage →

Or browse all 24 protocols: Open the Console →

Not ready? Book a counseling session first →

Already have your genome with Atlas?

See Atlas Baseline